Managing Specialty Drugs Under the Medical Benefit


Managing Specialty Drugs Under the Medical Benefit: Each year, there are an increasing number of biologics and specialty drugs produced for a number of rare and chronic conditions.

With more of these drugs coming down the pipeline, and faster drug approvals, payors and plan sponsors  continue to seek effective management strategies that support the health and productivity of their workforce, drive optimal patient outcomes, address data transparency issues and positively impact the bottom line.

AMI’s new report, Specialty Pharmaceuticals Benefit Management, looks at specialty drugs billed through the Medical Benefit.